BLACK BOX WARNING
- thyroid C-cell tumors in rodents at all doses tested; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
exenatide
Brand: Byetta, Bydureon BCise
⚠ BBW Prototype: liraglutide
Drug Class: GLP-1 receptor agonist
Drug Family: antidiabetic
Subclass: short-acting (exenatide) and extended-release (Bydureon) GLP-1 agonist
Organ Systems: endocrine
Mechanism of Action
Exendin-4 analog that activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing glucagon. Also delays gastric emptying, reduces appetite via hypothalamic GLP-1R, and promotes satiety. Cardiovascular and renal benefits are increasingly recognized.
GLP-1 receptor (GLP-1R)
Indications
- type 2 diabetes mellitus
Contraindications
- personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- severe GI disease
Adverse Effects
Common
- nausea (most common; up to 44%)
- vomiting
- diarrhea
- injection site reactions
Serious
- pancreatitis
- acute kidney injury (dehydration from GI side effects)
- medullary thyroid carcinoma (rodent data; relevance to humans unclear)
Pharmacokinetics (ADME)
| Absorption | subcutaneous injection; immediate-release given twice daily; Bydureon given once weekly |
| Distribution | Vd ~28 L |
| Metabolism | proteolytic degradation |
| Excretion | renal (glomerular filtration of degradation products) |
| Half-life | 2.4 hours (immediate-release); ~2 weeks (extended-release) |
| Onset | immediate (IR); delayed (ER) |
| Peak | 2 hours (IR) |
| Duration | 8 hours (IR); 1 week (ER) |
| Protein Binding | minimal |
| Vd | 28 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| oral medications | delayed gastric emptying may reduce absorption rate of oral drugs | moderate |
| warfarin | changes in absorption kinetics; monitor INR | moderate |
Nursing Considerations
- Administer IR formulation within 60 minutes before morning and evening meals; do not administer after meals.
- Nausea is dose-dependent and typically improves after 4–8 weeks; start at lower dose and titrate.
- Ensure adequate hydration especially when GI side effects are present; monitor renal function.
- Store unused pens in refrigerator; in-use pen can be kept at room temperature for up to 30 days.
Clinical Pearls
- Exenatide was the first GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster protein exendin-4.
- Unlike liraglutide and semaglutide, the immediate-release exenatide does not have demonstrated cardiovascular benefit (EXSCEL trial: CV-neutral), though Bydureon has demonstrated potential benefits.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.